AURA
Price
$6.30
Change
+$0.28 (+4.65%)
Updated
Dec 3 closing price
Capitalization
400.07M
117 days until earnings call
Intraday BUY SELL Signals
DYN
Price
$20.09
Change
+$0.10 (+0.50%)
Updated
Dec 3 closing price
Capitalization
2.87B
84 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AURA vs DYN

Header iconAURA vs DYN Comparison
Open Charts AURA vs DYNBanner chart's image
Aura Biosciences
Price$6.30
Change+$0.28 (+4.65%)
Volume$140.92K
Capitalization400.07M
Dyne Therapeutics
Price$20.09
Change+$0.10 (+0.50%)
Volume$2.54M
Capitalization2.87B
AURA vs DYN Comparison Chart in %
AURA
Daily Signal:
Gain/Loss:
DYN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AURA vs. DYN commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AURA is a StrongBuy and DYN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (AURA: $6.02 vs. DYN: $20.00)
Brand notoriety: AURA and DYN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AURA: 27% vs. DYN: 74%
Market capitalization -- AURA: $394.36M vs. DYN: $2.94B
AURA [@Biotechnology] is valued at $394.36M. DYN’s [@Biotechnology] market capitalization is $2.94B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AURA’s FA Score shows that 1 FA rating(s) are green whileDYN’s FA Score has 1 green FA rating(s).

  • AURA’s FA Score: 1 green, 4 red.
  • DYN’s FA Score: 1 green, 4 red.
According to our system of comparison, DYN is a better buy in the long-term than AURA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AURA’s TA Score shows that 4 TA indicator(s) are bullish while DYN’s TA Score has 3 bullish TA indicator(s).

  • AURA’s TA Score: 4 bullish, 5 bearish.
  • DYN’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both AURA and DYN are a bad buy in the short-term.

Price Growth

AURA (@Biotechnology) experienced а -1.47% price change this week, while DYN (@Biotechnology) price change was -3.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

AURA is expected to report earnings on Mar 31, 2026.

DYN is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DYN($2.87B) has a higher market cap than AURA($400M). DYN YTD gains are higher at: -15.110 vs. AURA (-26.764). AURA has higher annual earnings (EBITDA): -107.51M vs. DYN (-437.37M). DYN has more cash in the bank: 684M vs. AURA (177M). AURA has less debt than DYN: AURA (18.1M) vs DYN (121M). AURA (0) and DYN (0) have equivalent revenues.
AURADYNAURA / DYN
Capitalization400M2.87B14%
EBITDA-107.51M-437.37M25%
Gain YTD-26.764-15.110177%
P/E RatioN/AN/A-
Revenue00-
Total Cash177M684M26%
Total Debt18.1M121M15%
TECHNICAL ANALYSIS
Technical Analysis
AURADYN
RSI
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
85%
Momentum
ODDS (%)
Bullish Trend 6 days ago
72%
Bullish Trend 6 days ago
86%
MACD
ODDS (%)
Bullish Trend 6 days ago
84%
Bearish Trend 6 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
76%
Bullish Trend 6 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
76%
Bearish Trend 6 days ago
87%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 6 days ago
85%
Declines
ODDS (%)
Bearish Trend 14 days ago
84%
Bearish Trend 14 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 6 days ago
90%
Bullish Trend 6 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
AURA
Daily Signal:
Gain/Loss:
DYN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OAIEX15.24N/A
N/A
Optimum International A
GGSOX16.13N/A
N/A
Grandeur Peak Global Stalwarts Investor
MRIMX24.79N/A
N/A
Victory Integrity Mid-Cap Value R6
RSESX18.71N/A
N/A
Russell Inv US Strategic Equity S
TRZSX16.11N/A
N/A
T. Rowe Price Overseas Stock Z

AURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AURA has been loosely correlated with NUVL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AURA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AURA
1D Price
Change %
AURA100%
-3.06%
NUVL - AURA
48%
Loosely correlated
-1.37%
DSGN - AURA
47%
Loosely correlated
+0.11%
RGNX - AURA
46%
Loosely correlated
-3.10%
IDYA - AURA
46%
Loosely correlated
-1.75%
DYN - AURA
46%
Loosely correlated
-2.96%
More

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
-2.96%
RNA - DYN
61%
Loosely correlated
+0.27%
IDYA - DYN
56%
Loosely correlated
-1.75%
SYRE - DYN
55%
Loosely correlated
-0.91%
XNCR - DYN
53%
Loosely correlated
-3.15%
CRNX - DYN
51%
Loosely correlated
-0.53%
More